ESTIMATED
05/09/2024
05/09/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | -$0.47 | -$0.47 | -$0.47 |
Q2 2024 | 10 | -$1.01 | -$0.19 | -$0.53 |
Q3 2024 | 4 | -$0.52 | -$0.52 | -$0.52 |
Q4 2024 | 4 | -$0.90 | -$0.90 | -$0.90 |
Q1 2025 | 5 | -$0.89 | -$0.89 | -$0.89 |
Q2 2025 | 5 | -$0.81 | -$0.81 | -$0.81 |
Q3 2025 | 5 | -$0.85 | -$0.85 | -$0.85 |
Arrowhead Pharmaceuticals, Inc. last posted its earnings results on Thursday, May 9th, 2024. The company reported $-1.02 earnings per share for the quarter, missing analysts' consensus estimates of $-0.06 by $0.96. The company had revenue of 0 for the quarter and had revenue of 240.74 M for the year. Arrowhead Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.92 diluted earnings per share) and currently has a price-to-earnings ratio of -6.57. Arrowhead Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 5th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/09/2024 | Q2 2024 | -$0.06 | -$1.02 | -0.96 | $41.97 M | $0 | 02/06/2024 | Q1 2024 | -$0.78 | -$1.24 | -0.46 | $33.87 M | $3.55 M | 11/29/2023 | Q4 2023 | -$0.70 | -$1.02 | -0.32 | $16.10 M | 08/07/2023 | Q3 2023 | -$0.58 | -$0.96 | -0.38 | $15.83 M | 05/02/2023 | Q2 2023 | -$0.64 | $0.46 | 1.1 | $45.48 M | $146.27 M | 02/06/2023 | Q1 2023 | $1.14 | -$0.39 | -1.53 | $162.52 M | $62.55 M | 11/28/2022 | Q4 2022 | -$0.57 | -$0.81 | -0.24 | $31.58 M | 08/04/2022 | Q3 2022 | -$0.45 | -$0.67 | -0.22 | $32.41 M | 05/10/2022 | Q2 2022 | -$0.08 | $0.42 | 0.5 | $151.81 M | 02/02/2022 | Q1 2022 | -$0.22 | -$0.60 | -0.38 | $47.81 M | $27.44 M | 11/22/2021 | Q4 2021 | -$0.11 | -$0.61 | -0.5 | $42.19 M | $38.28 M | 08/05/2021 | Q3 2021 | -$0.08 | -$0.29 | -0.21 | $43.47 M | $45.89 M | 05/04/2021 | Q2 2021 | -$0.09 | -$0.26 | -0.17 | $32.81 M | 02/04/2021 | Q1 2021 | $1.00 | -$0.20 | -1.2 | $106.12 M | $21.30 M | 11/23/2020 | Q4 2020 | $0.34 | -$0.47 | -0.81 | $57.76 M | $7.63 M | 08/05/2020 | Q3 2020 | -$0.07 | -$0.13 | -0.06 | $30.42 M | $27.38 M | 05/07/2020 | Q2 2020 | -$0.11 | -$0.20 | -0.09 | $23.53 M | 02/05/2020 | Q1 2020 | -$0.01 | -$0.03 | -0.02 | $31.08 M | $29.45 M | 11/25/2019 | Q4 2019 | $0.16 | $0.12 | -0.04 | $40.98 M | $43.29 M | 08/05/2019 | Q3 2019 | $0.29 | $0.21 | -0.08 | $54.37 M | $42.70 M |
---|
A. Arrowhead Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 5th, 2024 based off last year's report dates.
A. The conference call for Arrowhead Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Arrowhead Pharmaceuticals, Inc.'s latest earnings report can be read online.
A. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a recorded annual revenue of $240.74 M.
A. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a recorded net income of $240.74 M. Arrowhead Pharmaceuticals, Inc. has generated $-1.92 earnings per share over the last four quarters.
A. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a price-to-earnings ratio of -6.57 and price/earnings-to-growth ratio is -0.31.